PE20040970A1 - FORMAS DE DOSIFICACION QUE COMPRENDEN UN INHIBIDOR DE LA PTEC Y UN INHIBIDOR DE LA HMG-CoA-REDUCTASA - Google Patents
FORMAS DE DOSIFICACION QUE COMPRENDEN UN INHIBIDOR DE LA PTEC Y UN INHIBIDOR DE LA HMG-CoA-REDUCTASAInfo
- Publication number
- PE20040970A1 PE20040970A1 PE2004000021A PE2004000021A PE20040970A1 PE 20040970 A1 PE20040970 A1 PE 20040970A1 PE 2004000021 A PE2004000021 A PE 2004000021A PE 2004000021 A PE2004000021 A PE 2004000021A PE 20040970 A1 PE20040970 A1 PE 20040970A1
- Authority
- PE
- Peru
- Prior art keywords
- coa
- inhibitor
- dosage
- hgm
- succinate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA FORMA DE DOSIFICACION UNITARIA QUE COMPRENDE: a) UNA COMPOSICION DE UN INHIBIDOR DE LA PROTEINA DE TRANSFERENCIA DE ESTERES DE COLESTERILO (PTEC) COMO TORCETRAPIB EN FORMA DE DISPERSION SOLIDA AMORFA Y UN POLIMERO ACIDO DE POTENCIADOR DE LA CONCENTRACION SELECCIONADO DEL GRUPO DE ACETATO-SUCCINATO DE HIDROXIPROPILMETIL-CELULOSA, SUCCINATO DE HIDROXIPROPILMETIL-CELULOSA, ENTRE OTROS Y b) UNA COMPOSICION DE UN INHIBIDOR DE LA HGM-CoA-REDUCTASA COMO ATORVASTATINA ESTAS DOS COMPOSICIONES SE COMBINA DE MODO TAL QUE AMBAS SE ENCUENTREN SUSTANCIALMENTE SEPARADAS ENTRE SI EN LA FORMA DE DOSIFICACION, EVITANDO ASI QUE EL POLIMERO ACIDO POTENCIADOR DE LA CONCENTRACION NO PRODUZCA NIVELES INACEPTABLES DE DEGRADACION QUIMICA DEL INHIBIDOR DE LA HGM-CoA-REDUCTASA, ESTA FORMA DE DOSIFICACION UNITARIA SE CARACTERIZA POR COMPRENDER UNA PLURALIDAD DE GRANULOS DE CADA UNO DE SUS CONSTITUYENTES, O AL MENOS DOS CAPAS, DICHAS FORMAS SON COMPRIMIDO, COMPRIMIDO OBLONGO, PILDORAS, CAPSULA, POLVO Y UN KIT QUE LOS COMPRENDE.TAMBIEN SE REFIERE A UN METODO PARA LA ELABORACION DE ESTA FORMA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43534502P | 2002-12-20 | 2002-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20040970A1 true PE20040970A1 (es) | 2004-12-14 |
Family
ID=32682223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004000021A PE20040970A1 (es) | 2002-12-20 | 2004-01-05 | FORMAS DE DOSIFICACION QUE COMPRENDEN UN INHIBIDOR DE LA PTEC Y UN INHIBIDOR DE LA HMG-CoA-REDUCTASA |
Country Status (24)
Country | Link |
---|---|
US (1) | US7897175B2 (es) |
EP (1) | EP1581210B1 (es) |
JP (1) | JP2006512359A (es) |
KR (1) | KR20050088190A (es) |
CN (1) | CN1728995A (es) |
AR (1) | AR042534A1 (es) |
AT (1) | ATE389396T1 (es) |
AU (1) | AU2003286372A1 (es) |
BR (1) | BR0317593A (es) |
CA (1) | CA2509688A1 (es) |
CO (1) | CO5590898A2 (es) |
DE (1) | DE60319877T2 (es) |
ES (1) | ES2300628T3 (es) |
GT (1) | GT200300295A (es) |
IL (1) | IL169090A0 (es) |
NL (1) | NL1025070C (es) |
NO (1) | NO20052779L (es) |
PE (1) | PE20040970A1 (es) |
PL (1) | PL377606A1 (es) |
RU (1) | RU2005119176A (es) |
TW (1) | TW200420301A (es) |
UY (1) | UY28134A1 (es) |
WO (1) | WO2004056359A1 (es) |
ZA (1) | ZA200504123B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
CA2455288A1 (en) * | 2001-06-21 | 2003-01-03 | Pfizer Products Inc. | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
CA2450748A1 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
BRPI0516772A (pt) * | 2004-10-25 | 2008-09-23 | Japan Tobacco Inc | formulação sólida com solubilidade e estabilidade melhoradas e método para produção da referida formulação |
AP2007003979A0 (en) * | 2004-11-23 | 2007-06-30 | Warner Lambert Co | 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia |
WO2006085217A2 (en) * | 2005-02-08 | 2006-08-17 | Pfizer Products Inc. | Solid adsorbates of hydrophobic drugs |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US8828438B2 (en) | 2005-05-31 | 2014-09-09 | Bend Research, Inc. | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase |
CA2618255C (en) | 2005-08-08 | 2015-05-26 | Abbott Gmbh & Co. Kg | Itraconazole compositions with improved bioavailability |
JP2009504590A (ja) * | 2005-08-08 | 2009-02-05 | アボット ゲーエムベーハー ウント コンパニー カーゲー | 改善された生物学的利用能をもつ剤型 |
DE102005049293A1 (de) * | 2005-10-15 | 2007-04-26 | Bayer Healthcare Ag | Kombinationspräparate von Salzen oder o-Acetylsalicylsäure |
US7351853B2 (en) * | 2006-01-23 | 2008-04-01 | Albion Advanced Nutrition | Method of manufacturing a granular mineral composition |
KR100791256B1 (ko) * | 2006-03-17 | 2008-01-03 | 주식회사 대웅제약 | 약학적으로 유용하고 안정한 아토바스타틴 고체분산체 및이를 포함하는 조성물 |
US20070269503A1 (en) * | 2006-05-16 | 2007-11-22 | James Walter Burgess | Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof |
AU2007300071A1 (en) * | 2006-09-27 | 2008-04-03 | Dr. Reddy's Laboratories Ltd. | Atorvastatin pharmaceutical compositions |
WO2008065506A2 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions comprising nanoparticles comprising enteric polymers and casein |
AR071706A1 (es) * | 2008-05-15 | 2010-07-07 | Otsuka Pharma Co Ltd | Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion. |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
CN103200935A (zh) | 2010-11-04 | 2013-07-10 | 霍夫曼-拉罗奇有限公司 | 包含2-甲基丙硫代酸s-[2-([[1-(2-乙基丁基)-环己基]-羰基]氨基)苯基]酯和交联羧甲基纤维素钠的组合物 |
KR101298788B1 (ko) * | 2011-03-15 | 2013-08-22 | 보령제약 주식회사 | 안정성이 개선된 복합제제 |
WO2012170417A2 (en) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
US8313774B1 (en) | 2012-06-26 | 2012-11-20 | Magnifica Inc. | Oral solid composition |
MA40590A (fr) * | 2014-08-28 | 2017-07-05 | Dezima Pharma B V | Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et des inhibiteurs de hmg-coa réductase |
JP2019131472A (ja) * | 2016-05-31 | 2019-08-08 | 興和株式会社 | 医薬組成物 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5180589A (en) | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
EP0680320B1 (en) | 1993-01-19 | 1999-04-14 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
DK0828495T3 (da) | 1995-06-01 | 2003-02-24 | Searle & Co | Misoprostolholdige faste stabiliserede dispersioner |
DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
ATE250929T1 (de) * | 1997-05-30 | 2003-10-15 | Osmotica Corp | Mehrlagige osmosevorrichtung |
US6235311B1 (en) | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
AU2157400A (en) * | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications |
EP1970052A2 (en) * | 1999-02-09 | 2008-09-17 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
EP1027888B1 (en) * | 1999-02-10 | 2009-06-10 | Pfizer Products Inc. | Osmotic system for delivery of solid amorphous dispersions of drugs |
WO2001093860A1 (en) * | 2000-06-09 | 2001-12-13 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
US6620821B2 (en) * | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
HUP0303083A3 (en) * | 2000-08-15 | 2005-05-30 | Pfizer Prod Inc | Pharmaceutical compositions containing therapeutic combination of a cetp inhibitor and atorvastatin and their use |
US20020077348A1 (en) | 2000-11-21 | 2002-06-20 | Dean Herbert M. | Dosage unit for cardioprotection |
US20040235935A1 (en) * | 2001-06-12 | 2004-11-25 | Francis Vanderbist | Oral pharmaceutical composition containing a statin derivative |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
CA2508840A1 (en) | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
US20040132771A1 (en) | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
-
2003
- 2003-12-12 JP JP2004561902A patent/JP2006512359A/ja active Pending
- 2003-12-12 ES ES03777117T patent/ES2300628T3/es not_active Expired - Lifetime
- 2003-12-12 PL PL377606A patent/PL377606A1/pl not_active Application Discontinuation
- 2003-12-12 CN CNA2003801069589A patent/CN1728995A/zh active Pending
- 2003-12-12 AU AU2003286372A patent/AU2003286372A1/en not_active Abandoned
- 2003-12-12 KR KR1020057011269A patent/KR20050088190A/ko not_active Application Discontinuation
- 2003-12-12 BR BR0317593-6A patent/BR0317593A/pt not_active IP Right Cessation
- 2003-12-12 CA CA002509688A patent/CA2509688A1/en not_active Abandoned
- 2003-12-12 WO PCT/IB2003/006087 patent/WO2004056359A1/en active IP Right Grant
- 2003-12-12 DE DE60319877T patent/DE60319877T2/de not_active Revoked
- 2003-12-12 EP EP03777117A patent/EP1581210B1/en not_active Revoked
- 2003-12-12 RU RU2005119176/15A patent/RU2005119176A/ru not_active Application Discontinuation
- 2003-12-12 AT AT03777117T patent/ATE389396T1/de not_active IP Right Cessation
- 2003-12-18 NL NL1025070A patent/NL1025070C/nl not_active IP Right Cessation
- 2003-12-18 TW TW092135977A patent/TW200420301A/zh unknown
- 2003-12-18 US US10/739,567 patent/US7897175B2/en not_active Expired - Fee Related
- 2003-12-18 AR ARP030104713A patent/AR042534A1/es unknown
- 2003-12-18 UY UY28134A patent/UY28134A1/es not_active Application Discontinuation
- 2003-12-19 GT GT200300295A patent/GT200300295A/es unknown
-
2004
- 2004-01-05 PE PE2004000021A patent/PE20040970A1/es not_active Application Discontinuation
-
2005
- 2005-05-20 ZA ZA200504123A patent/ZA200504123B/en unknown
- 2005-06-08 NO NO20052779A patent/NO20052779L/no not_active Application Discontinuation
- 2005-06-09 IL IL169090A patent/IL169090A0/en unknown
- 2005-06-17 CO CO05059491A patent/CO5590898A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20050088190A (ko) | 2005-09-02 |
UY28134A1 (es) | 2004-07-30 |
WO2004056359A1 (en) | 2004-07-08 |
CO5590898A2 (es) | 2005-12-30 |
AU2003286372A1 (en) | 2004-07-14 |
NL1025070C (nl) | 2010-04-06 |
DE60319877T2 (de) | 2009-04-30 |
BR0317593A (pt) | 2005-11-22 |
CN1728995A (zh) | 2006-02-01 |
NO20052779D0 (no) | 2005-06-08 |
IL169090A0 (en) | 2007-07-04 |
DE60319877D1 (de) | 2008-04-30 |
JP2006512359A (ja) | 2006-04-13 |
PL377606A1 (pl) | 2006-02-06 |
CA2509688A1 (en) | 2004-07-08 |
ATE389396T1 (de) | 2008-04-15 |
ES2300628T3 (es) | 2008-06-16 |
RU2005119176A (ru) | 2006-01-20 |
NO20052779L (no) | 2005-08-25 |
US7897175B2 (en) | 2011-03-01 |
US20040197398A1 (en) | 2004-10-07 |
EP1581210A1 (en) | 2005-10-05 |
NL1025070A1 (nl) | 2004-06-22 |
AR042534A1 (es) | 2005-06-22 |
TW200420301A (en) | 2004-10-16 |
EP1581210B1 (en) | 2008-03-19 |
ZA200504123B (en) | 2006-02-22 |
GT200300295A (es) | 2004-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20040970A1 (es) | FORMAS DE DOSIFICACION QUE COMPRENDEN UN INHIBIDOR DE LA PTEC Y UN INHIBIDOR DE LA HMG-CoA-REDUCTASA | |
ES2563305T3 (es) | Dispositivo de colágeno y procedimiento de preparación del mismo | |
AR123811A2 (es) | Composiciones de células madre mesenquimáticas purificadas y métodos relacionados | |
RU2010143440A (ru) | Декоративные косметические композиции | |
AR048028A1 (es) | 5,6-dialquil-7-amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos, asi como productos que las contienen | |
HN2008001104A (es) | Compuestos para anticuerpos de dickpf-1 y70-4 | |
BR112012033091A2 (pt) | método de cimentação, e, composição de cimento | |
RU2010143445A (ru) | Солнцезащитные композиции | |
EA200800595A1 (ru) | Композиции политиоуретана и способы получения и применения композиций политиоуретана | |
ATE542803T1 (de) | Verfahren zur herstellung von dihydrochinazolinen | |
BRPI0511482A (pt) | incorporação sìtio-especìfica de aminoácidos artificiais contendo átomos pesados em proteìnas para determinação de estrutura cristalina | |
NZ586439A (en) | Method for peforming an immunodiffusion assay (SRID) for influenza hemagglutinin antigen based on desorbing the antigen from the aluminium adjuvant salt | |
CO6341637A2 (es) | \\\\\\\"composiciones y metodos novedosos\\\\\\\" | |
DE602005020643D1 (de) | Verfahren zur aktivierung von nkt-zellen | |
UY29440A1 (es) | Nuevos compuestos | |
EA201170698A1 (ru) | Изоляция зон поглощения | |
CO6280567A2 (es) | Establecimiento de un anticuerpo monoclonal para detector de proteinas pag en la circulacion | |
AR064327A1 (es) | Un metodo para preparar montelukast e intermediarios utilizados en el mismo | |
EA201300008A1 (ru) | Недорогие электродные чипы (варианты) и способы многокомпонентного анализа и оценки на основе катодной электролюминесценции | |
DE602004017107D1 (de) | Verfahren zur Herstellung von (Meth)acrylsäure mit verringertem Wassergehalt | |
ATE368091T1 (de) | Elektrolumineszenz-vorrichtung sowie verfahren zu ihrer herstellung | |
ES2632933T3 (es) | Composición de limpieza de enzimas y método de uso | |
DE502006003030D1 (de) | Verwendung von inhibitoren des na+/h+ austauschers, subtyp 5 (nhe5) zur gedächtnisverbesserung | |
AR065847A1 (es) | Composicion portadora de rapida accion para la insercion de acido nucleico. metodo. uso. | |
JP2006526389A5 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |